Aptevo

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Aptevo and other ETFs, options, and stocks.

About APVO

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.

CEO

Marvin L. White

CEOMarvin L. White

Employees

Employees42

Headquarters

Seattle, Washington

HeadquartersSeattle, Washington

Founded

2016

Founded2016

Employees

Employees42

APVO Key Statistics

Market cap

8.25M

Market cap8.25M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

743.33K

Average volume743.33K

High today

$8.94

High today$8.94

Low today

$8.64

Low today$8.64

Open price

$8.67

Open price$8.67

Volume

32.78K

Volume32.78K

52 Week high

$1,807.20

52 Week high$1,807.20

52 Week low

$7.66

52 Week low$7.66

Stock Snapshot

Aptevo(APVO) stock is priced at $8.81, giving the company a market capitalization of 8.25M.

On 2026-01-14, Aptevo(APVO) stock moved within a range of $8.64 to $8.94. With shares now at $8.81, the stock is trading +2.0% above its intraday low and -1.5% below the session's peak.

Trading activity shows a volume of 32.78K, compared to an average daily volume of 743.33K.

Over the past 52 weeks, Aptevo(APVO) stock has traded between a high of $1,807.20 and a low of $7.66.

APVO News

TipRanks 5d

Aptevo Therapeutics Secures $60 Million Equity Financing Facility

Claim 70% Off TipRanks Premium Aptevo Therapeutics ( (APVO) ) has issued an announcement. On January 8, 2026, Aptevo Therapeutics entered into a $60 million s...

People also own

Based on the portfolios of people who own APVO. This list is generated using Robinhood data, and it’s not a recommendation.